REG-Shire Limited: Notification of major interests in shares

.
Notification of major interests in shares

Basingstoke, UK and Philadelphia, US - June 18, 2008 - Shire Limited (LSE: SHP,
NASDAQ: SHPGY), the global specialty biopharmaceutical company

1. Identity of the issuer or the underlying issuer of existing shares to which
voting rights are attached:

Shire Limited

2. Reason for the notification State
Yes/No

An acquisition or disposal of voting rights Yes

An acquisition or disposal of financial instruments which
may result in the acquisition of shares already issued to
which voting rights are attached

An event changing the breakdown of voting rights

Other (please specify): New Exemption DTR 5.1.3 (4) & DTR Yes
5.1.5 (1)

3. Full name of person(s) subject to the notification The Goldman Sachs
obligation: Group Inc

4. Full name of shareholder(s) (if different from 3.): Goldman, Sachs & Co.,

Goldman Sachs
Financial Markets,
L.L.C.

Goldman Sachs
Execution and
Clearing, L.P

5. Date of the transaction (and date on which the 16 June 2008
threshold is crossed
or reached if different):

6. Date on which issuer notified: 18 June 2008

7. Threshold(s) that is/are crossed or reached: Below 3%

8. Notified details:

A: Voting rights attached to shares

Class/type of Situation previous to Resulting situation after the triggering
shares the Triggering transaction
if possible transaction
using the ISIN
CODE

Number Number Number Number of voting % of voting
of of of rights rights
Shares Voting shares
Rights

Direct Direct Indirect Direct Indirect

GB00B0KQX869 115,000 0.021%

US82481R1068 17,114,532 3.059%
(5,704,844
ADRs)

B: Financial Instruments

Resulting situation after the triggering transaction

Type of Expiration Exercise/ Number of voting % of
financial date Conversion rights that may be voting
instrument Period/ Date acquired if the rights
instrument
is exercised/converted

Total (A+B)

Number of voting rights % of voting rights

Below 3%

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:

We hereby notify you that as at close of business on 16 June 2008, The Goldman
Sachs Group, Inc., of 85 Broad Street, New York, NY 10004, USA, no longer has a
notifiable interest in shares.

Proxy Voting:

10. Name of the proxy holder: N/A

11. Number of voting rights proxy holder will cease to hold: N/A

12. Date on which proxy holder will cease to hold voting N/A
rights:

13. Additional information: General Email Contact:
shareholderdisclosures@gs.com

14. Contact name: Sean Rogers/Alan Cox

15. Contact telephone number: 0207-552-9205 / 0207-774 -8774

Contact at Shire Limited: Tony Guthrie, Deputy Company Secretary, 01256 894746

For further information please contact:

Investor Relations Cl�a Rosenfeld (Rest of the World) +44 1256 894 160

Eric Rojas (North America) +1 484 595 8252

Media Jessica Mann (Rest of the World) +44 1256 894 280

Matthew Cabrey (North America) +1 484 595 8248

Jessica Cotrone (North America) +1 617 613 4640

Notes to editors

SHIRE LIMITED

Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit and hyperactivity disorder (ADHD),
human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The
structure is sufficiently flexible to allow Shire to target new therapeutic
areas to the extent opportunities arise through acquisitions. Shire's
in-licensing, merger and acquisition efforts are focused on products in niche
markets with strong intellectual property protection either in the US or
Europe. Shire believes that a carefully selected portfolio of products with
strategically aligned and relatively small-scale sales forces will deliver
strong results.

For further information on Shire, please visit the Company's website:
www.shire.com.

2

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

3

Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com

Press Release

Registered in England 5492592Registered Office as above

END
nPRrJ5AA9a